Breaking News, Collaborations & Alliances

Oxford BioTherapeutics, Menarini Progress AML Antibody

Select first clinical development candidate in oncology alliance

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) have selected a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical candidate under the companies’ oncology collaboration. The companies have initiated studies to support an application for a Phase I trial in AML patients in 2H14.   The therapeutic candidate incorporates BioWa ADCC-enhancing technology and has completed in vitro/ex vivo proof-of-concept, demonstrating efficacy, and exploratory ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters